AbbVie Inc. $ABBV Shares Sold by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 5.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 243,994 shares of the company’s stock after selling 14,740 shares during the quarter. Mawer Investment Management Ltd.’s holdings in AbbVie were worth $45,290,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ABBV. Brighton Jones LLC raised its stake in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the last quarter. Marks Group Wealth Management Inc raised its stake in AbbVie by 3.3% during the first quarter. Marks Group Wealth Management Inc now owns 2,143 shares of the company’s stock valued at $449,000 after buying an additional 69 shares in the last quarter. Bleakley Financial Group LLC lifted its holdings in AbbVie by 11.6% during the 1st quarter. Bleakley Financial Group LLC now owns 66,616 shares of the company’s stock worth $13,957,000 after buying an additional 6,934 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its stake in AbbVie by 9.3% during the first quarter. Rice Hall James & Associates LLC now owns 5,144 shares of the company’s stock worth $1,078,000 after purchasing an additional 437 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Trading Down 0.4%

Shares of NYSE:ABBV opened at $218.31 on Tuesday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a market capitalization of $385.84 billion, a price-to-earnings ratio of 103.96, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 1-year low of $163.81 and a 1-year high of $244.81. The company has a 50 day moving average price of $223.40 and a 200 day moving average price of $202.94.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is 524.24%.

Analyst Ratings Changes

ABBV has been the subject of a number of recent research reports. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Wall Street Zen upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a report on Tuesday, November 4th. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the stock from $170.00 to $270.00 in a research report on Wednesday, September 17th. Finally, Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $236.57.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.